Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of enasidenib versus conventional care in older adults with relapsed or refractory IDH2-mutant acute myeloid leukemia
2015-000344-42Phase 3Completed
- Sponsor
- Celgene Corporation
- Start
- Oct 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of enasidenib in acute myeloid leukemia (AML) (2 arms), sponsored by Celgene Corporation. Primary endpoint: Overall survival. Started Oct 2015; status: completed.
02
Drugs
enasidenib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2015-000344-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-000344-42.